KR20030033002A - 그렐린 길항제 - Google Patents

그렐린 길항제 Download PDF

Info

Publication number
KR20030033002A
KR20030033002A KR10-2003-7000982A KR20037000982A KR20030033002A KR 20030033002 A KR20030033002 A KR 20030033002A KR 20037000982 A KR20037000982 A KR 20037000982A KR 20030033002 A KR20030033002 A KR 20030033002A
Authority
KR
South Korea
Prior art keywords
ser
peptide
leu
pro
octanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2003-7000982A
Other languages
English (en)
Korean (ko)
Inventor
데겐기로마노
Original Assignee
아다나 바이오싸이언스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아다나 바이오싸이언스 리미티드 filed Critical 아다나 바이오싸이언스 리미티드
Publication of KR20030033002A publication Critical patent/KR20030033002A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
  • Steroid Compounds (AREA)
KR10-2003-7000982A 2000-07-24 2001-07-10 그렐린 길항제 Withdrawn KR20030033002A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22017800P 2000-07-24 2000-07-24
US60/220,178 2000-07-24
PCT/EP2001/007929 WO2002008250A2 (en) 2000-07-24 2001-07-10 Ghrelin antagonists

Publications (1)

Publication Number Publication Date
KR20030033002A true KR20030033002A (ko) 2003-04-26

Family

ID=22822394

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7000982A Withdrawn KR20030033002A (ko) 2000-07-24 2001-07-10 그렐린 길항제

Country Status (9)

Country Link
US (1) US20020187938A1 (https=)
EP (1) EP1303538A2 (https=)
JP (1) JP2004504406A (https=)
KR (1) KR20030033002A (https=)
CN (1) CN1443198A (https=)
AU (1) AU2001283938A1 (https=)
CA (1) CA2416643A1 (https=)
MX (1) MXPA03000738A (https=)
WO (1) WO2002008250A2 (https=)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157227A1 (en) * 2001-05-10 2004-08-12 Chopin Lisa Kerstin Reproductive cancer diagnosis and therapy
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
ATE441429T1 (de) * 2002-07-19 2009-09-15 Cytos Biotechnology Ag Ghrelin-träger-konjugate
CA2491946C (en) 2002-07-23 2013-05-28 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Ghrelin analogs
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004261329B2 (en) 2003-07-31 2011-10-27 Ocera Therapeutics, Inc. Spatially-defined macrocyclic compounds useful for drug discovery
CA2533820C (en) * 2003-07-31 2016-12-13 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
EP1663289A2 (en) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
ES2300686T3 (es) * 2003-10-16 2008-06-16 F. Hoffmann-La Roche Ag Peptidos sw grelina marcados fluorescentemente.
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US20090149512A1 (en) * 2004-05-14 2009-06-11 Novo Nordisk A/S Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases
CN101094689B (zh) 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
US7187208B2 (en) * 2005-01-19 2007-03-06 Phaselink Semiconductor Corporation Complimentary metal oxide silicon low voltage positive emitter coupled logic buffer
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
CA2625920C (en) 2005-09-28 2014-12-23 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogs of ghrelin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625447C (en) 2005-09-29 2015-06-09 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compositions and methods for stimulating gastrointestinal motility
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
US8992928B2 (en) 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
JP2010526878A (ja) * 2007-05-14 2010-08-05 エル ディクソン、スザンヌ 化学物質嗜癖のための新たな治療
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2493910A1 (en) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20160235807A1 (en) 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
BR112023002957A2 (pt) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401939T3 (es) * 1999-07-23 2013-04-25 Kenji Kangawa Nuevos péptidos
US6967237B2 (en) * 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs

Also Published As

Publication number Publication date
EP1303538A2 (en) 2003-04-23
AU2001283938A1 (en) 2002-02-05
MXPA03000738A (es) 2003-06-04
WO2002008250A3 (en) 2002-08-22
CN1443198A (zh) 2003-09-17
WO2002008250A2 (en) 2002-01-31
JP2004504406A (ja) 2004-02-12
US20020187938A1 (en) 2002-12-12
CA2416643A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
KR20030033002A (ko) 그렐린 길항제
US8518893B2 (en) Medical compositions containing ghrelin
FI95202C (fi) Menetelmä diabetes mellituksen hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
US20080020016A1 (en) Pharmaceutical compositions for sustained release delivery of peptides
US4603120A (en) Cyclic octapeptides and pharmaceutical preparations thereof, as well as processes for their manufacture, and their use
JPH05508616A (ja) 治療用エアロゾル剤
US9303067B2 (en) Sustained release formulation comprising a somatostatin analogue
US20070027073A1 (en) Long-acting derivatives of pyy agonists
US6362164B1 (en) Combination of a somatostatin analogue and a rapamycin
US4598065A (en) Use of peptides as medicaments and certain novel peptides
LV11596B (en) Long-acting injection susoensions and a process for their preparation
US20160045572A1 (en) Peptides comprising non-natural amino acids and methods of making and using the same
AU2004251866B2 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
KR100876538B1 (ko) Ｌｈｒｈ 길항제의 염의 제조방법
EP1632244B1 (en) Preventives or remedies for hepatopathy
JPH01308235A (ja) ヒト成長ホルモン経鼻剤
EP1756142B1 (en) Pseudopeptides growth hormone secretagogues

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid